Trichomegaly and Trichiasis Associated with Pemigatinib

A 30-year-old woman with metastatic intrahepatic cholangiocarcinoma was started on pemigatinib, a fibroblast growth factor receptor (FGFR) inhibitor, which was recently approved by the US Food and Drug Administration. Her baseline eye examination before starting pemigatinib was normal. Six weeks later, she developed ocular irritation. Her examiation revealed lengthened wire-like eyelashes (Fig A, right eye; Fig B, left eye) with lash-corneal touch (Fig C, right eye; Fig D, left eye) and punctate epithelial erosions.